Dolutegravir Has No Effect on the Pharmacokinetics of Oral Contraceptives With Norgestimate and Ethinyl Estradiol

Background: Dolutegravir (DTG; Tivicay; ViiV Healthcare, Research Triangle Park, NC) is an HIV-1-unboosted integrase inhibitor with no cytochrome P450 or uridine 5′diphosphate-glucuronosyltransferase inhibition or induction. As DTG is administered to HIV-1–infected women receiving oral contraceptive...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Ivy H., Borland, Julie, Chen, Shuguang, Wajima, Toshihiro, Peppercorn, Amanda F., Piscitelli, Stephen C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2015
Materias:
Research Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4472613/
https://www.ncbi.nlm.nih.gov/pubmed/25862012
http://dx.doi.org/10.1177/1060028015580637

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4472613/
https://www.ncbi.nlm.nih.gov/pubmed/25862012
http://dx.doi.org/10.1177/1060028015580637

Ejemplares similares